FAYETTEVILE, N.C. (WTVD) -- Fayetteville native John Rowell calls the FDA's approval of the first injectable treatment for HIV pre-exposure prevention, PrEP, "monumental." The FDA said the injectable ...

HIV is preventable, yet new diagnoses continue in AZ at higher-than-average rates. Could a new, twice-yearly shot called ...

According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...

The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Add Yahoo as a preferred source to see more of our stories on Google. a group of fit men in blue and white outfits promote national prep day Today is the first National PrEP Day — a new annual event ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

Eswatini joined a handful of countries to officially roll out new HIV prevention drug lenacapavir on Wednesday, announcing ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...